Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: Results of randomised double blind placebo-controlled study of cerebrolysin

Aim. To, assess therapeutic and prophylactic effect of large-dose cerebroly sin (15 ml/day for 28 days) in hypertensive and atherosclerotic patients wi th cognitive disorders. Material and methods. Cerebrolysin was given annually (15 ml/day for 28 day s) for 2 years to 42 patients in a randomized double-blind placebo-controll ed study. The effect was stated by clinical status, neuropsychological and neurophysiological data. Results. In mild disturbances of cognitive functions in patients with arter ial hypertension and atherosclerosis courses of cerebrolysin with one-year interval produce stable improvement of subjective status, productivity of m emory, attention and thinking which persist for at least a year after the c ourse. The clinical data agree with positive trend in neurophysiological pa rameters of cognitive component of the response of evoked potentials P-300. Conclusion. A course of 28-day annual treatment with cerebrolysin (15 ml/da y) of patients with mild defects of cognitive functions stabilizes the proc ess, leads to regression of cognitive disorders predicting vascular dementi a.